Cleared Traditional

ARTROMOT-E, ELBOW / ARTROMOT-S, SHOULDER CMP MOD. (K933059) - FDA 510(k) Clearance

Class I Physical Medicine device.

Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jun 1994
Decision
365d
Days
Class 1
Risk

K933059 is an FDA 510(k) clearance for the ARTROMOT-E, ELBOW / ARTROMOT-S, SHOULDER CMP MOD.. Classified as Exerciser, Powered (product code BXB), Class I - General Controls.

Submitted by Jace Systems, Inc. (Moorestown, US). The FDA issued a Cleared decision on June 22, 1994 after a review of 365 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Physical Medicine FDA review panel, regulated under 21 CFR 890.5380 - the FDA physical medicine device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Elevated predicate reliance profile. This clearance follows a standard predicate-based equivalence path within the Physical Medicine review framework, consistent with the majority of Class II 510(k) submissions.

View all Jace Systems, Inc. devices

Submission Details

510(k) Number K933059 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received June 22, 1993
Decision Date June 22, 1994
Days to Decision 365 days
Submission Type Traditional
Review Panel Physical Medicine (PM)
Summary Statement
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
250d slower than avg
Panel avg: 115d · This submission: 365d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code BXB Exerciser, Powered
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 890.5380
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.